Psoriasis: Recommendations for cyclosporine

Indication: adult, nonimmunocompromised patients with severe, recalcitrant psoriasis
  • Severe is defined by the FDA as extensive or disabling plaque psoriasis
  • Recalcitrant is defined by the FDA as those patients who have failed to respond to at least one systemic therapy or in patients for whom other systemic therapies are contraindicated, or cannot be tolerated
  • Some guidelines suggest use of cyclosporine in moderate to severe psoriasis
  • Efficacy observed in erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar psoriasis

Strength of Recommendation: B Level of Evidence: II   

Navigate section 4 of the psoriasis guideline: Systemic agents

Citation note

When referencing this guideline in a publication, please use the following citation: Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009 Sep;61(3):451-85. 

View the AAD guidelines disclaimer.